Home Administrative Billing & Reimbursement Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

New policy for Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, or Antiepileptics

March 28, 2017

AmeriHealth has created a policy to communicate the medical necessity criteria for therapeutic drug monitoring (TDM) of antidepressants, antipsychotics, and antiepileptic medications. Medical Policy #06.02.55: Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, or Antiepileptics was posted as a Notification on March 8, 2017, and goes into effect April 7, 2017.

Medically necessary criteria

TDM for antidepressants, antipsychotics, and antiepileptic medications is considered medically necessary, and, therefore, covered for any of the following reasons when a plan is in place to use the test findings clinically:

  • dose optimization after initial prescription or dose change;
  • suspected complete or partial non-adherence or non-compliance to prescribed medication;
  • lack of clinical improvement under recommended dose;
  • clinical improvement under recommended dose but with adverse effects;
  • initiation of combination therapy with a drug known for its interaction potential or suspected drug interaction;
  • relapse prevention under maintenance treatment.

Coverage limits

When the above criteria are met, TDM is considered medically necessary, and, therefore, covered for the following number of units:

  • Antidepressants: A combined maximum of up to 15 units of tests per calendar year.
    • – CPT® codes: 80332, 80333, 80334, 80335, 80336, 80337, 80338
  • Antiepileptics: A combined maximum of up to 15 units of tests per calendar year.
    • – CPT codes: 80339, 80340, 80341, 80355, 80366, 80156, 80157, 80164, 80165, 80168, 80171, 80175, 80177, 80183,
      80184, 80185 , 80186, 80188, 80199, 80201, 80203
  • Antipsychotics: A combined maximum of up to 15 units of tests per calendar year.
    • – CPT codes: 80342, 80343, 80344, 80159, 80173, 80178

Specimen validity/adulteration testing is not eligible for separate reimbursement, as this is considered part of the laboratory quality control practice.

More information

To view the Notifications for these policies, visit our Medical Policy Portal and select Accept and Go to Medical Policy Online. Then select Commercial under Active Notifications.

If you have any questions, please contact your Provider Partnership Associate or Network Coordinator.

CPT copyright 2016 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of AmeriHealth, AmeriHealth HMO, Inc., AmeriHealth Insurance Company of New Jersey.
© 2023 AmeriHealth Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer